secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001104659-25-079816
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio updates corporate presentation; posts preliminary cash of $8.8M as of June 30, 2025
--------------------------------------------------------------------------------

- Preliminary cash of $8.8M as of June 30, 2025; audited FY2025 results expected later this quarter.
- IBIO-610 (Activin E antibody) showed 8.9% body weight loss, 26% fat reduction, no lean mass loss in DIO mice.
- IBIO-610 + semaglutide achieved 35.3% weight loss vs 27.8% alone; prevented weight regain after GLP-1 cessation.
- IBIO-600 (anti-myostatin) half-life 40-52 days in NHPs; human estimate 57-147 days; CMC and GLP tox ongoing.
- Partnered with AstralBio to develop amylin receptor agonist antibodies for obesity treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465925079816/0001104659-25-079816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465925079816/tm2523706d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-079816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer